BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dellinger TH, Han ES. State of the Science: The role of HIPEC in the treatment of ovarian cancer. Gynecol Oncol 2021;160:364-8. [PMID: 33419611 DOI: 10.1016/j.ygyno.2020.12.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ghirardi V, Trozzi R, Scambia G, Fagotti A. Current and future trials about HIPEC in ovarian cancer. Bull Cancer 2023:S0007-4551(23)00082-6. [PMID: 36863924 DOI: 10.1016/j.bulcan.2023.01.016] [Reference Citation Analysis]
2 Lim PQ, Han IH, Seow KM, Chen KH. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers. Int J Mol Sci 2022;23:10078. [PMID: 36077477 DOI: 10.3390/ijms231710078] [Reference Citation Analysis]
3 Liu P, Ye M, Wu Y, Wu L, Lan K, Wu Z. Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes. Cancer Med 2023;12:3201-21. [PMID: 35908281 DOI: 10.1002/cam4.5085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He TF, Lee P, Razavi M, Liang WS, Schmolze D, Priceman SJ, Lee S, Lin WC, Lin JF, Kebria M, Hakim A, Ruel N, Stewart DB, Wang EW, Paz BI, Wakabayashi MT, Cristea MC, Rodriguez-Rodriguez L. Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. JCO Precis Oncol 2022;6:e2100239. [PMID: 35357903 DOI: 10.1200/PO.21.00239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Qi Y, Zhang Y, Shi Y, Yao S, Dai M, Cai H. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial. Technol Cancer Res Treat 2022;21:15330338221104565. [PMID: 35929135 DOI: 10.1177/15330338221104565] [Reference Citation Analysis]
6 Morikov D, Shelekhov A, Gorbachev VI, Dvornichenko V, Pavlov A, Radostev S. Some features of intraoperative infusion-transfusion therapy when performing cytoreductive operations with the use of hyperthermic intraperitoneal chemotherapy in patients with ovarian cancer: retrospective cohort study. Annals of critical care 2021. [DOI: 10.21320/1818-474x-2021-3-126-132] [Reference Citation Analysis]